GlycoNAVI: CheGly (Chemical Glycosylation)
ACT

Cleistetroside-2

ID Compound Name Target Name Species Assay Method Activity Value Conditions DOI
act2212Cleistetroside-2Staphylococcus aureus ATCC33591 (oxacillin-resistant)MIC (μg/mL)2 - 410.1021/ml300303g
act2214Cleistetroside-2Coagulase-negative staphylococciMIC (μg/mL)>3210.1021/ml300303g
act2216Cleistetroside-2Enterococcus faecalisMIC (μg/mL)2 - 410.1021/ml300303g
act2218Cleistetroside-2Bacillus spp.MIC (μg/mL)210.1021/ml300303g
act2220Cleistetroside-2Streptococcus pneumoniaeMIC (μg/mL)410.1021/ml300303g
act2222Cleistetroside-2Corynebacterium spp.MIC (μg/mL)1610.1021/ml300303g
act2224Cleistetroside-2viridans group streptococciMIC (μg/mL)410.1021/ml300303g
act2227Cleistetroside-2E. coli MG1655MIC (μM)>6410.1021/ml300303g
act2235Cleistetroside-2E. coli impMIC (μM)>6410.1021/ml300303g
act2243Cleistetroside-2B. subtilis JH642MIC (μM)410.1021/ml300303g
act2251Cleistetroside-2NCI-H460MIC (μM)9.110.1021/ml300303g
act2259Cleistetroside-2RPMI-8226 (leukemia)GI50 (μM)1.8610.1021/ml300303g
act2265Cleistetroside-2SR (leukemia)GI50 (μM)1.4510.1021/ml300303g
act2271Cleistetroside-2A549 (nonsmall cell lung cancer)GI50 (μM)9.4710.1021/ml300303g
act2277Cleistetroside-2NCI-H460 (nonsmall cell lung cancer)GI50 (μM)7.5810.1021/ml300303g
act2283Cleistetroside-2HCT-15 (colon cancer)GI50 (μM)7.5410.1021/ml300303g
act2289Cleistetroside-2HT-29 (colon cancer)GI50 (μM)8.0210.1021/ml300303g
act2295Cleistetroside-2SF-539 (CNS cancer)GI50 (μM)4.7010.1021/ml300303g
act2301Cleistetroside-2SNB-75 (CNS cancer)GI50 (μM)1.3610.1021/ml300303g
act2307Cleistetroside-2MDA-MB-435 (melanoma)GI50 (μM)6.0010.1021/ml300303g
act2313Cleistetroside-2SK-MEL-5 (melanoma)GI50 (μM)1.7610.1021/ml300303g
act2319Cleistetroside-2OVCAR-3 (ovarian cancer)GI50 (μM)4.8410.1021/ml300303g
act2325Cleistetroside-2ADR-R (ovarian cancer)GI50 (μM)9.1510.1021/ml300303g
act2331Cleistetroside-2A498 (renal cancer)GI50 (μM)7.5710.1021/ml300303g
act2337Cleistetroside-2CAKI-1 (renal cancer)GI50 (μM)8.4510.1021/ml300303g
act2343Cleistetroside-2PC-3 (prostate cancer)GI50 (μM)5.3010.1021/ml300303g
act2349Cleistetroside-2DU-145 (prostate cancer)GI50 (μM)7.9210.1021/ml300303g
act2355Cleistetroside-2MCF7 (breast cancer)GI50 (μM)1.7410.1021/ml300303g
act2361Cleistetroside-2BT-549 (breast cancer)GI50 (μM)8.4610.1021/ml300303g
act2367Cleistetroside-2S. aureus ATCC 33591MIC (μg/mL)0.510.1021/ml300303g
act2370Cleistetroside-2S. aureus 78-13607AMIC (μg/mL)110.1021/ml300303g
act2372Cleistetroside-2Staphylococcus aureus ATCC 29213 (oxacillin-susceptible)MIC (μg/mL)4Phase I10.1021/ml300303g
act2374Cleistetroside-2Staphylococcus aureus ATCC 33591 (oxacillin-resistant)MIC (μg/mL)2Phase I10.1021/ml300303g
act2376Cleistetroside-2Staphylococcus epidermidis clinical isolate 12-1788A (oxacillin-susceptible)MIC (μg/mL)>32Phase I10.1021/ml300303g
act2378Cleistetroside-2Staphylococcus haemolyticus clinical isolate 107-1240C (oxacillin-resistant)MIC (μg/mL)32Phase I10.1021/ml300303g
act2380Cleistetroside-2Enterococcus faecalis ATCC 29212 (ampicillin-susceptible, vancomycin-susceptible)MIC (μg/mL)2Phase I10.1021/ml300303g
act2382Cleistetroside-2Enterococcus faecium clinical isolate 24-45A (ampicillin-resistant, vancomycin-resistant)MIC (μg/mL)2Phase I10.1021/ml300303g
act2384Cleistetroside-2Streptococcus pneumoniae ATCC 49619 (penicillin-intermediate)MIC (μg/mL)4Phase I10.1021/ml300303g
act2386Cleistetroside-2Streptococcus pneumoniae clinical isolate 33-50B (penicillin-resistant)MIC (μg/mL)4Phase I10.1021/ml300303g
act2388Cleistetroside-2Corynebacterium jeikium clinical isolate 15-196A (wild-type)MIC (μg/mL)32Phase I10.1021/ml300303g
act2390Cleistetroside-2Bacillus cereus clinical isolate 24-59A (wild-type)MIC (μg/mL)2Phase I10.1021/ml300303g
act2392Cleistetroside-2Streptococcus pyogenes clinical isolate 91-8747 (erythromycin-resistant)MIC (μg/mL)4Phase I10.1021/ml300303g
act2394Cleistetroside-2Streptococcus mitis clinical isolate 61-2900C (penicillin-resistant)MIC (μg/mL)4Phase I10.1021/ml300303g
act2396Cleistetroside-2Pseudomonas aeruginosa ATCC 27853MIC (μg/mL)32Phase I10.1021/ml300303g
act2398Cleistetroside-2Escherichia coli ATCC 25922MIC (μg/mL)>32Phase I10.1021/ml300303g
act2400Cleistetroside-2Staphylococcus aureus 4-90A (mupirocin-resistant)MIC (μg/mL)2 - 4Phase II10.1021/ml300303g
act2402Cleistetroside-2Staphylococcus aureus 300-12053A (quinupristin/dalfopristin-resistant)MIC (μg/mL)2 - 4Phase II10.1021/ml300303g
act2404Cleistetroside-2Staphylococcus aureus 106-12591A (linezolid-resistant)MIC (μg/mL)2 - 4Phase II10.1021/ml300303g
act2406Cleistetroside-2Coagulase-negative staphylococci 63-18A (mupirocin-resistant)MIC (μg/mL)>32Phase II10.1021/ml300303g
act2408Cleistetroside-2Coagulase-negative staphylococci 90-10840A (quinupristin/dalfopristin-resistant)MIC (μg/mL)>32Phase II10.1021/ml300303g
act2410Cleistetroside-2Coagulase-negative staphylococci 82-1645A (linezolid-resistant)MIC (μg/mL)>32Phase II10.1021/ml300303g
act2412Cleistetroside-2Enterococcus faecalis 48-22D (vancomycin-resistant,vanA phenotype)MIC (μg/mL)2 - 4Phase II10.1021/ml300303g
act2414Cleistetroside-2Enterococcus faecalis 82-876D (vancomycin-resistant, vanB phenotype)MIC (μg/mL)2 - 4Phase II10.1021/ml300303g
act2416Cleistetroside-2Enterococcus faecalis 15-534I (linezolid-resistant)MIC (μg/mL)2 - 4Phase II10.1021/ml300303g
act2418Cleistetroside-2Enterococcus faecalis 39-11D (high-level gentamicin and streptomycin-resistant)MIC (μg/mL)2 - 4Phase II10.1021/ml300303g
act2420Cleistetroside-2Enterococcus faecium 15-206A (vancomycin-resistant, vanA phenotype)MIC (μg/mL)2 - 4Phase II10.1021/ml300303g
act2422Cleistetroside-2Enterococcus faecium 103-1232D (vancomycin-resistant, vanB phenotype)MIC (μg/mL)2 - 4Phase II10.1021/ml300303g
act2424Cleistetroside-2Enterococcus faecium 11-4103A (linezolid-resistant)MIC (μg/mL)2 - 4Phase II10.1021/ml300303g
act2426Cleistetroside-2Enterococcus faecium 65-1208A (quinupristin/dalfopristin-resistant)MIC (μg/mL)2 - 4Phase II10.1021/ml300303g
act2428Cleistetroside-2Bacillus spp. 107-1461D (tetracycline-resistant)MIC (μg/mL)2Phase II10.1021/ml300303g
act2430Cleistetroside-2Bacillus spp. 67-1057A (trimethoprim/ sulfamethoxazole-resistant)MIC (μg/mL)2Phase II10.1021/ml300303g
act2432Cleistetroside-2Bacillus spp. 32-2406A (erythromycin-resistant)MIC (μg/mL)2Phase II10.1021/ml300303g
act2434Cleistetroside-2Streptococcus pneumoniae 68-2307B (multidrug-resistant)MIC (μg/mL)4Phase II10.1021/ml300303g
act2436Cleistetroside-2Streptococcus pneumoniae 4-38B (erythromycin-resistant, clindamycin-resistant)MIC (μg/mL)4Phase II10.1021/ml300303g
act2438Cleistetroside-2Streptococcus pneumoniae 35-405B (erythromycin-resistant, clindamycin-susceptible)MIC (μg/mL)4Phase II10.1021/ml300303g
act2440Cleistetroside-2Streptococcus pneumoniae 2-2784A (levofloxacin-resistant)MIC (μg/mL)4Phase II10.1021/ml300303g
act2442Cleistetroside-2Corynebacterium spp. 105-1513C (doxycycline-resistant)MIC (μg/mL)16Phase II10.1021/ml300303g
act2444Cleistetroside-2Corynebacterium spp. 58-9161A (rifampin-resistant)MIC (μg/mL)16Phase II10.1021/ml300303g
act2446Cleistetroside-2Corynebacterium spp. 61-5454A (high-level streptomycin-resistant)MIC (μg/mL)16Phase II10.1021/ml300303g
act2448Cleistetroside-2β-haemolytic streptococci 91-526D (erythromycin-resistant, clindamycin-resistant)MIC (μg/mL)4Phase II10.1021/ml300303g
act2450Cleistetroside-2β-haemolytic streptococci 109-820D (erythromycin-resistant, clindamycin-susceptible)MIC (μg/mL)4Phase II10.1021/ml300303g
act2452Cleistetroside-2β-haemolytic streptococci 19-756A (levofloxacin-resistant)MIC (μg/mL)4Phase II10.1021/ml300303g
act2454Cleistetroside-2viridans group streptococci 32-2395A (mupirocin-resistant)MIC (μg/mL)4Phase II10.1021/ml300303g
act2456Cleistetroside-2viridans group streptococci 107-6380A (levofloxacin-resistant)MIC (μg/mL)4Phase II10.1021/ml300303g
act2458Cleistetroside-2viridans group streptococci 27-2832A (linezolid-resistant)MIC (μg/mL)4Phase II10.1021/ml300303g
act2460Cleistetroside-2viridans group streptococci 58-1602D (multidrug-resistant)MIC (μg/mL)4Phase II10.1021/ml300303g